Search results
Results From The WOW.Com Content Network
Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it. Since ...
Its market cap is down to $15 billion. Compared to revenue of $5 billion and $9 billion in cash on the balance sheet, Moderna is an interesting opportunity for a turnaround bet at current prices.
Moderna's strategy in 2025 focuses on maintaining its COVID-19 immunization market share while advancing its late-stage candidate pipeline. ... a significant sum relative to its current market ...
The Motley Fool recommends Marvell Technology, Moderna, and Southwest Airlines and recommends the following options: long January 2026 $395 calls on Microsoft, short February 2025 $27 calls on ...
The following is a list of publicly traded companies having the greatest market capitalization, sometimes described as their "market value": [1]. Market capitalization is calculated by multiplying the share price on a selected day and the number of outstanding shares on that day.
There was good news to share, but the market focused on a declining sales forecast and hammered the stock lower. Last November, Moderna said it expected 2024 revenue to land in a range between $3 ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
I believe my numbers are right. 2022, this company did $19 billion in revenue with COVID vaccines, and $2 billion average for 2025, that is a change of heart in terms of the market for COVID vaccines.